Previous studies have shown INHBA to be markedly up-regulated in colorectal cancer, cervical cancer, breast cancer, gastric cancer, lung adenocarcinoma and other cancers, correlating strongly with aggressive disease and adverse survival.49–53 Our data corroborate these findings, and extend them by dissecting how INHBA remodels the TME and restrains ferroptosis in CRC, mechanisms that had remained undefined. The gene discussed is INHBA; the disease is breast carcinoma.